The pan-European STOXX 600 index gained 0.2 per cent, after ending Friday with its biggest two-week percentage increase since 2015.

Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-...

Novartis AG on Thursday scrapped the $1 billion sale of U.S. generic pill and skin drug assets to India's Aurobindo Pharma Ltd as regulator...

An inexpensive drug widely used since 1955 to treat malaria, Hydroxychloroquine is considered to have relatively harmless side effects. It ...

Other companies including Bayer and Teva have also agreed to donate hydroxychloroquine or similar drugs, while Gilead Sciences is testing i...

Our chief focus for future investments will be: One on increasing our R&D footprint here over time. Second is data and digital.

India remains on Priority Watch List, and continues to be singled out for what the USTR considers to be inadequate protection of intellectu...

Cipla, India’s fifthlargest drugmaker by revenue, has asked the government to revoke five patents that Novartis holds on respiratory drug O...

Despite efforts globally, sales of fake medicines are rising rapidly, and the menace could be worse than the health threat posed by Big Tob...

MNC durgmakers on Wednesday hit back at their domestic counterparts over frivolous patent issue and said even the local firms are engaged i...

PepsiCo's Indra Nooyi and Novartis' Daniel Vasella discuss challenges before post-crisis 21st century corporations.

Insulin brands, steroids and painkillers may become more expensive once NPPA revises prices of more than 170 medicines, in some cases by as...

According to a research, the Indian pharma market in rural areas has witnessed a 39% growth.